This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pellikainen, J. Articles by Kosma, V.-M. Search for Related Content PubMed PubMed Citation Articles by Pellikainen, J. Articles by Kosma, V.-M.

Reduced Nuclear Expression of Transcription Factor AP-2 Associates with Aggressive Breast Cancer¹

Department of Pathology and Forensic Medicine, University of Kuopio [J. P., J. B., V-M. K.] and Departments of Pathology [K. R., T. P., V-M. K.], Oncology [V. K.], Surgery [M. E.] and Otorhinolaryngology, Oral and Maxillofacial Unit [J. K.], Kuopio University Hospital, FIN-70211 Kuopio, Finland

Purpose: We proposed to investigate the expression and prognostic significance of activator protein 2 (AP-2) in breast cancer.

Experimental Design: AP-2 was immunohistochemically analyzed in a prospective, consecutive series of 420 breast cancer patients diagnosed and treated between 1990 and 1995 at Kuopio University Hospital, Kuopio, Finland. AP-2 expression was further compared with clinicopathological parameters and patients’ survival.

Results: Nuclear AP-2 expression was lower in carcinomas compared with normal ductal breast epithelium (P < 0.001). Nuclear expression was more often seen in lobular than in ductal or other carcinomas (P = 0.048). Cytoplasmic staining was present in 47% of the carcinomas. Low nuclear AP-2 expression level in carcinomas was associated with advanced stage (P = 0.002), axillary lymph node positivity (P = 0.012), poor differentiation (P = 0.001), and recurrences (P = 0.003). In univariate survival analyses, low nuclear AP-2 expression (P = 0.0028), advanced stage (P < 0.0001), lymph node metastases (P < 0.0001), and poor differentiation (P = 0.0498) predicted shorter recurrence-free survival (RFS). Low nuclear AP-2 staining and/or shift to cytoplasmic expression predicted shorter RFS (P = 0.0050) and breast cancer-related survival (BCRS; P = 0.0314) in univariate analyses. Cytoplasmic expression alone did not have prognostic value. In multivariate analysis, low nuclear AP-2 expression (P = 0.0292) and advanced stage (P = 0.0001) were independent predictors of shorter RFS; and stage (P < 0.0001) and ER-status (P = 0.0321) independently predicted BCRS. In the lymph-node positive patients, RFS was independently predicted by stage (P = 0.0110) and nuclear AP-2 status (P = 0.0151).

Conclusions: AP-2 seems to have a protective role in breast cancer. Low nuclear AP-2 expression was associated with disease progression and increased metastatic capability of the tumor. In addition, reduced nuclear AP-2 expression independently predicted elevated risk of recurrent disease in breast cancer.

This article has been cited by other articles:

				F. Orso, E. Penna, D. Cimino, E. Astanina, F. Maione, D. Valdembri, E. Giraudo, G. Serini, P. Sismondi, M. De Bortoli, et al. AP-2{alpha} and AP-2{gamma} regulate tumor progression via specific genetic programs FASEB J, August 1, 2008; 22(8): 2702 - 2714. [Abstract] [Full Text] [PDF]

				W.-G. Deng, G. Jayachandran, G. Wu, K. Xu, J. A. Roth, and L. Ji Tumor-specific Activation of Human Telomerase Reverses Transcriptase Promoter Activity by Activating Enhancer-binding Protein-2beta in Human Lung Cancer Cells J. Biol. Chem., September 7, 2007; 282(36): 26460 - 26470. [Abstract] [Full Text] [PDF]

				D. Ng, O. Toure, M.-H. Wei, D. C. Arthur, F. Abbasi, L. Fontaine, G. E. Marti, J. F. Fraumeni Jr, L. R. Goldin, N. Caporaso, et al. Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia Blood, February 1, 2007; 109(3): 916 - 925. [Abstract] [Full Text] [PDF]

				V. X. Jin, A. Rabinovich, S. L. Squazzo, R. Green, and P. J. Farnham A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data--A case study using E2F1 Genome Res., December 1, 2006; 16(12): 1585 - 1595. [Abstract] [Full Text] [PDF]

				T. Egener, E. Roulet, M. Zehnder, P. Bucher, and N. Mermod Proof of concept for microarray-based detection of DNA-binding oncogenes in cell extracts Nucleic Acids Res., May 12, 2005; 33(8): e79 - e79. [Abstract] [Full Text] [PDF]

				R. I. Aqeilan, A. Palamarchuk, R. J. Weigel, J. J. Herrero, Y. Pekarsky, and C. M. Croce Physical and Functional Interactions between the Wwox Tumor Suppressor Protein and the AP-2{gamma} Transcription Factor Cancer Res., November 15, 2004; 64(22): 8256 - 8261. [Abstract] [Full Text] [PDF]

				J. M. Pellikainen, K. M. Ropponen, V. V. Kataja, J. K. Kellokoski, M. J. Eskelinen, and V.-M. Kosma Expression of Matrix Metalloproteinase (MMP)-2 and MMP-9 in Breast Cancer with a Special Reference to Activator Protein-2, HER2, and Prognosis Clin. Cancer Res., November 15, 2004; 10(22): 7621 - 7628. [Abstract] [Full Text] [PDF]

				S. B. Fox, J. Braganca, H. Turley, L. Campo, C. Han, K. C. Gatter, S. Bhattacharya, and A. L. Harris CITED4 Inhibits Hypoxia-Activated Transcription in Cancer Cells, and Its Cytoplasmic Location in Breast Cancer Is Associated with Elevated Expression of Tumor Cell Hypoxia-Inducible Factor 1{alpha} Cancer Res., September 1, 2004; 64(17): 6075 - 6081. [Abstract] [Full Text] [PDF]